Evidence map›Paper›PMID 40911949›Full record

Trial reportDrug metabolism and disposition: the biological fate of chemicals2025

Curcumin enhances the oral bioavailability of testosterone by inhibiting its intestinal metabolism.

Namrata Bachhav, Dilip Kumar Singh, Griffin Shaffer, John K Amory, Bhagwat Prasad

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Drug metabolism and disposition: the biological fate of chemicals, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Namrata BachhavDepartment of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, Washington.
Dilip Kumar SinghDepartment of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, Washington; Division of Translational and Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
Griffin ShafferDepartment of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, Washington; Division of Translational and Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
John K AmoryDepartment of Medicine, University of Washington, Seattle, Washington.
Bhagwat PrasadDepartment of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, Washington; Division of Translational and Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. Electronic address: bhagwat.prasad@cchmc.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hypogonadism, characterized by low testosterone blood levels, affects 3%-5% of males worldwide. Oral testosterone undecanoate (TU) is emerging as a key route of administration due to its better ease of administration; however, it suffers from variable pharmacokinetics and pharmacodynamics. The variability is majorly attributed to intestinal glucuronidation of testosterone to its hydrophilic metabolite, testosterone glucuronide (TG), formed by the polymorphic uridine 5'-diphospho-glucuronosyltransferase 2B17 (UGT2B17). This study investigated the potential of curcumin, as a UGT2B17 inhibitor, to enhance TU bioavailability using a series of in vitro and in vivo studies. In human intestinal microsomes, curcumin inhibited UGT2B17 with an IC

Indexed as

CurcuminGlucuronosyltransferaseIntestinal MucosaTestosteroneAdministration, OralAdultAndrostenedioneBiological AvailabilityCell LineCross-Over StudiesEnterocytesGlucuronidesHumansHypogonadismMaleMicrosomesAndrostenedioneCurcuminGlucuronidesGlucuronosyltransferaseMinor Histocompatibility AntigensTestosteronetestosterone glucuronatetestosterone undecanoateUGT2B17 protein, humanBioavailability boostingCurcuminHypogonadismIntestinal glucuronidationLiquid chromatography with tandem mass spectrometryTestosterone undecanoateUGT2B17

Identifiers

PMID40911949
PMCPMC12597537

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.